Randomised Trial of Clazosentan, an Endothelin Receptor Antagonist, in Patients with Aneurysmal Subarachnoid Hemorrhage Undergoing Surgical Clipping (CONSCIOUS-2)

Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1)

R. Loch Macdonald, Neal F. Kassell, Stephan A. Mayer et al. · Stroke · 2008 · 642 citations · Full text

Medicine, Neurosurgery, Pharmacotherapy +17

Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)

R. Loch Macdonald, Randall T. Higashida, E. Keller et al. · The Lancet Neurology · 2011 · 638 citations

Medicine, Neurosurgery, Surgery +14

Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations

Jens P. Dreier, Johannes Woitzik, Martin Fabricius et al. · Brain · 2006 · 565 citations · Full text

Medicine, Neurology, Neurosurgery +10

Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage

Stephan A. Mayer, Kurt T. Kreiter, Daphne Copeland et al. · Neurology · 2002 · 317 citations

Medicine, Neurology, Neurosurgery +17

Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study

Peter Vajkoczy, Bernhard Meyer, Stefan Weidauer et al. · Journal of neurosurgery · 2005 · 302 citations

Medicine, Neurosurgery, Pharmacotherapy +14